Marc Thibonnier, M.D.Founder & President at AptamiR Therapeutics
Dr. Thibonnier is a Physician-Scientist who received his Medical Degree with High Honors from the University of Paris, France, and his Master of Science Degree in Pharmacology from the University of California, San Francisco, where he completed his fellowship in clinical pharmacology.
He is board certified in internal medicine, endocrinology, and nephrology in Europe, and in internal medicine and clinical pharmacology in the USA.
He has held faculty positions at his alma mater in Paris, the University of California San Francisco, the Medical College of Ohio and Case Western Reserve University School of Medicine in Cleveland, Ohio, where he was a tenured Professor of Medicine and Pharmacology. He was a Clinical Professor of Medicine at Stanford University with teaching and clinical duties until 2015. He has kept an academic appointment as Professor of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida.
During his academic career, Dr. Thibonnier conducted basic research and clinical investigations in the cardiovascular and metabolic/endocrinology fields, supported by the American Heart Association, the United States Department of Veterans Affairs and the National Institute of Health (total of $21,554,542 in funding over two decades). He also completed clinical trials in the field of arterial hypertension, dyslipidemia and diabetes mellitus supported by various pharmaceutical sponsors and the NIH (ACCORD Trial). He has published 157 scientific articles and reviews.
Thereafter, Dr. Thibonnier spent 14 years in senior executive leadership positions at major Pharmaceutical (Bayer Health Care, BMS, and GSK) and two Biotechnology Startup Companies in the USA.
In 2012, Dr. Thibonnier founded AptamiR Therapeutics, Inc., to tackle the obesity pandemic and related cardio-metabolic disorders that afflict one third of the world population. He assembled a stellar team of physicians, scientists, drug developers and business experts to create an innovative model of modular and outsourced R&D to cure human obesity and related cardio-metabolic disorders by developing microRNA (miRNA)-based treatments that target peripheral adipose tissues (fat cells).